Summary of Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2016

Summary of Significant Accounting Policies

Schedule of the Company's net sales by medical indication

(In thousands)	For the Three Months Ended March 31,					For the Nine months Ended March 31,
Medical Indication	2016			2015		2016			2015
Antibiotic	$	3,160		$	3,005	$	8,716		$	9,355
Cardiovascular	16,652			8,457		38,059			45,729
Central Nervous System	14,264			—		20,351			—
Gallstone	14,698			20,489		53,389			48,969
Gastrointestinal	21,739			—		30,431			—
Glaucoma	6,006			5,714		19,371			15,921
Gout	59			1,453		206			6,743
Migraine	5,090			6,722		16,338			19,455
Muscle Relaxant	1,193			3,738		4,246			6,377
Obesity	1,023			1,084		2,853			2,952
Pain Management	7,178			4,286		23,386			18,508
Respiratory	5,308			—		6,703			—
Thyroid Deficiency	38,009			36,720		116,543			114,601
Urinary	6,506			—		10,148			—
Other	12,716			7,684		34,082			18,951
Contract manufacturing revenue	10,111			—		12,382			—
Net sales	163,712			99,352		397,204			307,561
Settlement agreement	(23,598		)	—		(23,598		)	—
Total net sales	$	140,114		$	99,352	$	373,606		$	307,561

Summary of products which accounted for at least 10% of net sales

	For the Three Months Ended March 31,				For the Nine months Ended March 31,
	2016		2015		2016		2015
Product 1	23	%	37	%	29	%	37	%
Product 2	9	%	21	%	13	%	16	%
Product 3	4	%	7	%	5	%	13	%

Summary of customers which accounted for at least 10% of net sales

	For the Three Months Ended March 31,				For the Nine months Ended March 31,
	2016		2015		2016		2015
Customer A	22	%	27	%	25	%	30	%
Customer B	17	%	15	%	16	%	10	%